Updated Jul 16, 2026
WEAVER GREGORY L is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market purchases: $49K.
Gregory L. Weaver is the Chief Financial Officer at Altimmune, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for obesity and metabolic diseases. He has been involved in the company through several SEC filings, indicating his role in its financial management.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-01 | ALT | Altimmune, Inc. | P — Open-market purchase | 10.0K | $3.15 | $31K |
| 2026-03-09 | ALT | Altimmune, Inc. | P — Open-market purchase | 5.0K | $3.54 | $18K |
Gregory L. Weaver is the Chief Financial Officer at Altimmune, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for obesity and metabolic diseases. He has been involved in the company through several SEC filings, indicating his role in its financial management.…
Recorded transactions: 2 open-market purchases ($49K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live WEAVER GREGORY L profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.